Tymlos (abaloparatide) NDC 70539-001

NDC codes

FDA NDC Directory

Product NDC (as listed)70539-001Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70539-0001Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70539-001-02	70539000102	1 CARTRIDGE in 1 BOX, UNIT-DOSE (70539-001-02) / 1.56 mL in 1 CARTRIDGE (70539-001-01)Marketed from May 1, 2017
70539-001-98	70539000198	1 CARTRIDGE in 1 BOX, UNIT-DOSE (70539-001-98) / 1.56 mL in 1 CARTRIDGE (70539-001-99)Marketed from May 1, 2017 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tymlos
Generic name (nonproprietary): abaloparatide
Active ingredients: Abaloparatide — 3.12 mg/1.56mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Radius Health, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 208743
Marketing start: May 1, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Parathyroid Hormone-Related Protein (Chemical structure)
Identifiers: Product ID 70539-001_f1834fb1-55c0-46ca-9da4-d03e867b3b8bSPL ID f1834fb1-55c0-46ca-9da4-d03e867b3b8bSPL set ID 712143d9-e21e-4013-bb3b-3426a21060a8RxCUI 1921075, 1921081UNII AVK0I6HY2U
Pharmacologic class: Parathyroid Hormone-Related Peptide Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470539000102 followed by a unit qualifier and the quantity

Package 70539-0001-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 11, 2026.

Indications (excerpt from the label)

TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.2 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)